Nevertheless, while the primary endpoint in the PRE-SURGE 2 trial does not appear to have any dose response, as you noted, the endpoints in PRE-SURGE 1 and the secondary endpoints in PRE-SURGE 2 appear to trend slightly better with the 160 mg dose.

FORBES: Regeneron Announces Strong Results In Gout Study

Prior to the FDA action, patients were required to get an infusion of rituximab the first day, followed by a pre-treatment diagnostic dose of radiolabeled indium-111 Zevalin.

FORBES: Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments